AgingResearch.NewsJoin free

Stroke or systemic embolism

There are 7 papers on stroke or systemic embolism in aging research: 2 trials and 3 observational studies in people, 2 reviews. The newest story, Oct 26, 2026: “Mitral valve repair is linked to better survival than replacement”.

Disease

7 papers study it40 more mention it10 findings

4 new papers in 30 daysSee all 47 papers on stroke or systemic embolism

“the risk of stroke or systemic embolism increased by 37% (adjusted HR 1.37, 95% CI 1.19-1.58)”
Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trialBMC medicine2020doi:10.1186/s12916-020-01870-w
  • Human trial2
  • Humans3

Interventions

3

Implantable loop recorder

no changein humans1

1 study

  1. Implantable loop recorder showed no clear effect on stroke or systemic embolism in humans (3.9% versus 3.8%).

    “During a median follow‐up of 5.5 years (interquartile range, 4.9–5.9 years), 55 (4%) developed the primary outcome with no difference between randomization groups (3.9% versus 3.8%, P=0.93, for ILR group and control group, respectively).”

    Human trialmedian follow‐up of 5.5 yearsn = 1,422

    Effects of Atrial Fibrillation Screening According to Echocardiographic Measures of Cardiac Structure and Function: A Post Hoc Analysis of the LOOP Randomized Clinical Trial

    Journal of the American Heart Association

More on Implantable loop recorder

Oral anticoagulant deprescribing

no changein humans1

1 study

  1. Oral anticoagulant deprescribing was not clearly linked with stroke or systemic embolism in humans (atrial fibrillation) (aOR 0.68, 95% CI 0.25-1.82).

    “OAT deprescription was associated with all-cause mortality [adjusted odds ratio (aOR) 1.41, 95% CI 1.68-1.85], along with older age, comorbidity burden, cognitive impairment, and functional dependence, but with neither SSE nor MB/CRNMB incidence”

    Humansatrial fibrillation1 yearn = 1,578

    Predictors and Outcomes of Oral Anticoagulant Deprescribing in Geriatric Inpatients With Atrial Fibrillation: A Retrospective Multicenter Cohort Study

    Journal of the American Medical Directors Association

More on Oral anticoagulant deprescribing

Edoxaban

no changein humans1

1 study

  1. Edoxaban showed no clear effect on stroke or systemic embolism in humans (compared with warfarin, in every frailty category).

    “Edoxaban was associated with similar efficacy to warfarin in every frailty category”

    Human trialcompared with warfarin, in every frailty categoryn = 20,867

    Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial

    BMC medicine

More on Edoxaban

Associations

6

Implantable loop recorder

downin humans1HR 0.38

1 study

  1. Implantable loop recorder lowers the risk of stroke or systemic embolism in the lowest tertile of LA contraction strain values (<16.5%) (62% lower risk, HR 0.38, 95% CI 0.16–0.87).

    “This corresponded to a 62% lower risk of stroke with randomization to ILR (HR, 0.38 [95% CI, 0.16–0.87], Figure ).”

    Human trialin the lowest tertile of LA contraction strain values (<16.5%)median follow‐up of 5.5 years

    Effects of Atrial Fibrillation Screening According to Echocardiographic Measures of Cardiac Structure and Function: A Post Hoc Analysis of the LOOP Randomized Clinical Trial

    Journal of the American Heart Association

  2. Implantable loop recorder lowers the risk of stroke or systemic embolism in humans (contraction strain<16.5%) (HR 0.38, 95% CI 0.16-0.87).

    “a lower risk of the primary outcome was noted from ILR with lower left atrial contraction strain values (hazard ratio [HR], 0.38 [95% CI, 0.16-0.87], for participants with contraction strain<16.5%)”

    Human trialcontraction strain<16.5%median follow-up of 5.5 yearsn = 1,422

    Effects of Atrial Fibrillation Screening According to Echocardiographic Measures of Cardiac Structure and Function: A Post Hoc Analysis of the LOOP Randomized Clinical Trial

    Journal of the American Heart Association

More on Implantable loop recorder

Asundexian

downin humans1RR 0.74

1 study

  1. Asundexian lowers the risk of stroke or systemic embolism in humans (cardiovascular disease; sensitivity analysis excluding an influential trial) (RR 0.74, 95% CI 0.65–0.84).

    “Sensitivity analyses excluding an influential trial reduced heterogeneity substantially and demonstrated a lower risk of stroke or systemic embolism (RR 0.74, 95% CI 0.65–0.84).”

    Reviewcardiovascular disease; sensitivity analysis excluding an influential trial

    Efficacy and Safety of Asundexian in Cardiovascular Diseases, Systemic Review and Meta-Analysis

    AHA Scientific Sessions 2026 abstract

More on Asundexian

Direct oral anticoagulants

downin humans1RR 0.3

1 study

  1. Direct oral anticoagulants lower the risk of stroke or systemic embolism in humans (patients with atrial fibrillation; compared with vitamin K antagonists) (pooled RR = 0.30; 95% CI, 0.26-0.34).

    “Meta-analysis results indicate a significantly lower risk of stroke or systemic embolism with DOACs (pooled RR = 0.30; 95% CI, 0.26-0.34)”

    Reviewpatients with atrial fibrillation; compared with vitamin K antagonists

    Comparative impact of direct oral anticoagulants and vitamin K antagonists on cognitive function in atrial fibrillation patients: a systematic review and meta-analysis

    Journal of medicine and life

More on Direct oral anticoagulants

Non-vitamin K antagonist oral anticoagulants

downin humans1

1 study

  1. Non-vitamin K antagonist oral anticoagulants are linked with a lower risk of stroke or systemic embolism in patients with AF and frailty compared with VKAs (aHR 0.77, 95% CI (0.70-0.86)).

    “NOACs were associated with lower risks of stroke or systemic embolism (stroke/SE) [aHR 0.77, 95%CI (0.70-0.86)]”

    Humansin patients with AF and frailty compared with VKAsn = 71,638

    Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study

    European heart journal. Quality of care & clinical outcomes

More on Non-vitamin K antagonist oral anticoagulants

High bleeding risk

upin humans1

1 study

  1. High bleeding risk is associated with stroke or systemic embolism in humans (4.8% vs. 2.0% per patient-year, log-rank P<0.001).

    “The crude incidence (% per patient-year) of adverse events was significantly higher in ELDERCARE-eligible than non-eligible patients (stroke/SE, 4.8% vs. 2.0%”

    HumansELDERCARE-AF trial eligibility criteria (≥80 years, CHADS2 score ≥2, and ≥1 bleeding risk factor) vs non-eligible

    Clinical Characteristics and Outcomes of Very Elderly Patients With Atrial Fibrillation at High Bleeding Risk - The Fushimi AF Registry

    Circulation reports

Frailty index

upin humans1HR 1.37

1 study

  1. Frailty index raises the risk of stroke or systemic embolism in humans (per 0.1 increase in frailty index) (+37%, adjusted HR 1.37, 95% CI 1.19-1.58).

    “the risk of stroke or systemic embolism increased by 37% (adjusted HR 1.37, 95% CI 1.19-1.58)”

    Human trialper 0.1 increase in frailty index0.1 increase in frailty indexn = 20,867

    Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial

    BMC medicine

More on Frailty index

Latest

Dec 2025: 2Jan 2026: 0Feb 2026: 2Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 1Oct 2026: 3Nov 2026: 110 papers in 12 months
ESC Congress 2026 Abstract

Mitral valve repair is linked to better survival than replacement

In an observational study of 19,844 patients, valve replacement was linked to a hazard ratio of 1.87 for death compared with repair.In an observational study of 19,844 patients, valve replacement was linked to a hazard ratio of 1.87 for death compared with repair.

Cohort · 19,844 peopleInterventions
Paper
ESC Congress 2026 Abstract

Empagliflozin reduced abnormal heart rhythms after bypass surgery

During 72-hour monitoring after surgery, abnormal heart rhythms occurred in 12.9% of patients given empagliflozin versus 26.8% given placebo.During 72-hour monitoring after surgery, abnormal heart rhythms occurred in 12.9% of patients given empagliflozin versus 26.8% given placebo.

Randomized trial · 467 peopleEmpagliflozin
Paper
Neurology

Early heart rhythm treatment linked to fewer repeat strokes or clots

Five-year hospitalization estimates for repeat stroke or clots elsewhere were 8.0% with early rhythm control versus 13.8% with usual care.Five-year hospitalization estimates for repeat stroke or clots elsewhere were 8.0% with early rhythm control versus 13.8% with usual care.

Cohort · 14,355 peopleInterventions
Paper

See all 47 papers on stroke or systemic embolism

Related